Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of azenosertib versus investigator's choice chemotherapy in cyclin E1-positive platinum-resistant ovarian cancer
2025-524641-27-00Phase 3Authorised
- Sponsor
- K-Group Beta, Inc.
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of azenosertib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by K-Group Beta, Inc. Primary endpoint: Progression-free survival. Planned start Oct 2026; status: authorised.
02
Drugs
azenosertib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2025-524641-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524641-27-00.